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Abstract
Tauopathies are a group of neurodegenerative diseases characterized by hyperphosphorylation of the microtubule-binding
protein, tau, and typically feature axon impairment and synaptic dysfunction. Cyclin-dependent kinase5 (Cdk5) is a major
tau kinase and its activity requires p35 or p25 regulatory subunits. P35 is subjected to rapid proteasomal degradation in its
membrane-bound form and is cleaved by calpain under stress to a stable p25 form, leading to aberrant Cdk5 activation and
tau hyperphosphorylation. The type Ib transmembrane protein RPS23RG1 has been implicated in Alzheimer’s disease (AD).
However, physiological and pathological roles for RPS23RG1 in AD and other tauopathies are largely unclear. Herein, we
observed retarded axon outgrowth, elevated p35 and p25 protein levels, and increased tau phosphorylation at major Cdk5
phosphorylation sites in Rps23rg1 knockout (KO) mice. Both downregulation of p35 and the Cdk5 inhibitor roscovitine
attenuated tau hyperphosphorylation and axon outgrowth impairment in Rps23rg1 KO neurons. Interestingly, interactions
between the RPS23RG1 carboxyl-terminus and p35 amino-terminus promoted p35 membrane distribution and proteasomal
degradation. Moreover, P301L tau transgenic (Tg) mice showed increased tau hyperphosphorylation with reduced
RPS23RG1 levels and impaired axon outgrowth. Overexpression of RPS23RG1 markedly attenuated tau hyperpho-
sphorylation and axon outgrowth defects in P301L tau Tg neurons. Our results demonstrate the involvement of RPS23RG1
in tauopathy disorders, and implicate a role for RPS23RG1 in inhibiting tau hyperphosphorylation through homeostatic p35
degradation and suppression of Cdk5 activation. Reduced RPS23RG1 levels in tauopathy trigger aberrant Cdk5-p35
activation, consequent tau hyperphosphorylation, and axon outgrowth impairment, suggesting that RPS23RG1 may be a
potential therapeutic target in tauopathy disorders.
Introduction
Tau is a microtubule-binding protein enriched in axons,
and functions to stabilize and regulate microtubule
structure and neuronal connectivity [1, 2]. Tau comprises
multiple phosphorylation sites, and its homeostatic
phospho-regulation is essential for physiological tau
function [3, 4]. In neurodegenerative tauopathy disorders
such as Alzheimer’s disease (AD) and frontotemporal
dementia, tau is hyperphosphorylated and accumulates in
neuronal cells, thereby leading to impaired microtubule
binding and axon dysfunction [5–8].
Cyclin-dependent kinase5 (Cdk5) is a proline-directed
serine/threonine protein kinase that plays a significant role
in axon growth, synapse development, and memory for-
mation [9–12]. Although Cdk5 is ubiquitously expressed,
its kinase activity is restricted in postmitotic neurons and
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requires interactions with regulatory p35 or p39 subunits for
activation [13, 14]. Although both p35 and p39 are
expressed in neurons, Cdk5 kinase activity is reduced by
90% in p35 knock out (KO) mouse brain, suggesting that
p35 is the primary Cdk5 activator in the brain [15, 16].
The Cdk5-p35 complex phosphorylates cytoskeletal pro-
teins such as tau, CRMP-2, and MAP1B to facilitate axon
outgrowth [17–19]. P35 is myristoylated within an amino
(N)-terminal glycine (G2) to facilitate its localization to
membranes and promote homeostatic p35 proteasomal
degradation [20, 21]. Moreover, Ca2+-dependent p35 clea-
vage by calpain generates a stable p25 fragment that con-
stitutively binds and activates Cdk5 [22]. Under stress
conditions such as β-amyloid (Aβ) exposure in AD, neu-
ronal calpain activity is enhanced, thereby inducing p35
cleavage and consequent p25-mediated Cdk5 activation.
Given that p25 lacks the N-terminal membrane-associated
myristoyl moiety, cytosolic Cdk5-p25 distribution enables
phosphorylation of an enhanced number of targets and
features an extended half-life compared to Cdk5-p35.
Aberrant activation of Cdk5 leads to tau hyperpho-
sphorylation and induces neuronal dysfunction [23, 24].
Cdk5 is relatively stable, while p35 has a short half-life
and is subjected to ubiquitin–dependent proteasomal
degradation. In addition to myristoylation-mediated degra-
dation mentioned above, p35 S-nitrosylation promotes its
ubiquitination and degradation by PJA2 [25]. Furthermore,
enhanced p35 turnover through the Sigma-1 receptor has
been shown to regulate axon extension [18]. As p35 is a
fundamental component in regulating tau phosphorylation
during axon growth and neurodegeneration, a comprehen-
sive understanding of p35 regulation may provide new
insight into mechanisms underlying the pathogenesis of
tauopathy disorders.
RPS23RG1 is a type Ib transmembrane protein abun-
dantly expressed in the central nervous system, including
neurons, astrocytes, and microglia. RPS23RG1 levels are
found to be reduced in postmortem human AD brain and
brain from AD mouse models. The RPS23RG1 trans-
membrane domain can interact with adenyl cyclases to
enhance cAMP/PKA/GSK3β signaling, thereby inhibiting
AD-associated amyloid-β (Aβ) generation and tau phos-
phorylation [26, 27]. The RPS23RG1 carboxyl (C)-
terminus can interact with post-synaptic density (PSD)
components PSD95 and PSD93 to inhibit their ubiquiti-
nation and proteasomal turnover [28]. Although these
findings implicate a role for RPS23RG1 dysfunction in
AD pathogenesis, how RPS23RG1 maintains physiolo-
gical brain function and its role in related tauopathy dis-
orders beyond AD has yet to be determined.
Herein, we identify a novel role for RPS23RG1 in
tauopathy and provide a mechanism by which RPS23RG1
maintains proper tau phosphorylation and axon outgrowth
through p35 interaction to promote homeostatic p35
degradation.
Materials and methods
Animals
Wild type (WT) C57BL/6 mice were obtained from the
Xiamen University Laboratory Animal Center (Xiamen,
China). Rps23rg1 knockout (KO) mice were generated and
maintained as previously described [28]. P301L tau Tg mice
were from The Jackson Lab and maintained by crossing a
CaMKIIα-tTA line with the Tg(tetO-tauP301L) line to
constitutively express human P301L tau primarily in fore-
brain neurons [29, 30]. Animal experiments were approved
by the Animal Ethics Committee of Xiamen University and
conducted following the Committee’s guidelines.
DNA constructs and siRNA
Plasmids expressing RPS23RG1 and its truncated forms
were generated previously [28]. HA-tagged RPS23RG2 was
cloned in the pCMV-HA plasmid (Clontech, Mountain
View, CA, USA). Myc-tagged full-length p35 and its
mutated and truncated forms, as well as tau and P301L
tau were cloned into the pcDNA 3.1-Myc-His plasmid
(Invitrogen, Carlsbad, CA, USA).
Scrambled control and p35-targeting siRNAs, as well as
their FAM-labeled oligos, were synthesized by GenePharma
(Shanghai, China). Their sequences were as follows:
p35-siRNA#1 (sense: 5’-GCAAGAACGCCAAGGACAAT
T-3’, antisense: 5’-UUGUCCUUGGCGUUCUUGCTT-3’),
p35-siRNA#2 (sense: 5’-GCAACAUCGCGCAUCUCAAT
T-3’, antisense: 5’-UUGAGAUGCGCGAUGUUGCTT-3’),
p35-siRNA#3 (sense: 5’-CCCACACUAUUUCACACAAT
T-3’, antisense: 5’-UUGUGUGAAAUAGUGUGGGTT-3’),
and scrambled control (sense: 5’-UUCUCCGAACGUG
UCACGUTT-3’, antisense: 5’-ACGUGACACGUUCGGAG
AATT-3’).
Antibodies and reagents
Antibodies used include anti-pS199 (44–734G), anti-pS396
(44–752G), anti-Tau5 (AHB0042), anti-pT205 (44–738G),
and anti-AT8 (MN1020) from Thermo Fisher (Waltham,
MA, USA); anti-pS404 (#20194), anti-p35 (#2680), anti-
pS9-GSK-3β (#9336), and anti-β-actin (#8457) from Cell
Signaling Technology (Danvers, MA, USA); anti-Myc
(M20002L) and anti-HA (M20003L) from Abmart (Ber-
keley Heights, CA, USA); anti-Cdk5 (sc-173) from Santa
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Cruz Biotechnology (Dallas, TX, USA); anti-GSK-3β
(51065-1-AP) from Proteintech (Chicago, IL, USA);
anti-ubiquitin (ab7780) from Abcam (Cambridge, UK); and
anti-Tuj1 (801201) from BioLegend (San Diego, CA,
USA). A monoclonal antibody targeting mouse RPS23RG1
was generated using the RPS23RG1 “QQRNIGYFNHLK”
epitope (Sino biological Inc., Beijing, China).
Roscovitine, TDZD-8, cycloheximide, and MG132 were
from MedChemExpress (Monmouth Junction, NJ, USA).
NH4Cl was from Sigma-Aldrich (Shanghai, China).
Cell culture and transfection
Human HEK293T cells and Hela cells were originally
from ATCC (Manassas, VA, USA) and maintained in our
laboratory. They were cultured in high-glucose DMEM
(Thermo Fisher) with 10% fetal bovine serum (Thermo
Fisher). HEK293/tau cells were maintained in the same
media with additional 200 μg/mL G418 (Thermo Fisher).
Plasmids were transfected into cells using Turbofect
transfection reagent (Thermo Fisher), according to the
manufacturer’s instructions.
Primary hippocampal neurons were prepared from
postpartum day 0 (P0) mouse pups and cultured in neu-
robasal medium (Thermo Fisher) supplied with 2% B27
(Thermo Fisher) and 1 mM glutamine (Thermo Fisher).
Primary neurons were transfected with plasmids using
EntransterTM-H4000 transfection reagent (Engreen Bio-
system, Beijing, China) at 1 or 3 day in vitro (DIV1 or
DIV3), or transfected with siRNAs using Lipofectamine
2000 reagent (Thermo Fisher) at DIV0 or DIV2, follow-
ing manufacturers’ protocols.
Western blot and co-immunoprecipitation (co-IP)
Proteins in mouse brain tissues or cells were assayed by
western blot and/or co-IP as previously described [28].
Protein band intensity was quantified using the ImageJ
software (National Institutes of Health, Bethesda,
MD, USA).
Immunofluorescence
Immunofluorescence of cells were carried out as previously
described [28, 31]. Cell images were acquired by confocal
microscopy (FV1000MPE-B, Olympus, Tokyo, Japan).
Longest neurites in cultured primary neurons were defined
as axon [32, 33]. Axon length was quantified using ImageJ.
Protein degradation assays
Primary neurons derived from Rps23rg1 KO and WT mice
and HEK293T cells transfected with RPS23RG1 were
treated with cycloheximide for indicated time periods, in the
presence or absence of MG132 and NH4Cl.
Membrane and cytosol protein fractionation
Membrane and cytosol proteins were separated using a
membrane/cytosol protein extraction kit from Beyotime
Institute of Biotechnology (Shanghai, China), and detected
by immunoblotting.
Statistics
All data were presented as mean ± SEM (standard error of
mean). Statistical analyses were carried out using GraphPad
Prism (GraphPad Software, San Diego, CA). Student’s
t-test was used to evaluate statistical significance between
groups.
Results
Rps23rg1 deletion results in increased tau
phosphorylation and impaired axon extension
We previously observed a reduced number of synapses
in primary neurons from Rps23rg1 KO mice compared
to wild type (WT) control mice [28]. To further study a
role for RPS23RG1 in neuronal development, we cultured
primary neurons derived from postnatal day 0 (P0)
Rps23rg1 KO and WT mice and characterized neurite
outgrowth in vitro after 2 (DIV2) or 4 (DIV4) days in
culture, where neurons were stained for Tuj-1 to show
neuronal morphology. Rps23rg1 KO neurons at DIV2
(Fig. 1a) and DIV4 (Fig. 1b) exhibited significantly
shorter axons (the longest neurite) compared to WT
neurons. As tau hyperphosphorylation can impair axonal
development [6, 18], we assessed the effects of Rps23rg1
deletion on tau phosphorylation. Total and phosphory-
lated tau levels in primary neurons (Fig. 1c) and hippo-
campal samples (Fig. 1d) from Rps23rg1 KO and
WT mice were compared. Although no significant
change in total tau (probed using the Tau5 antibody)
was detected in Rps23rg1 KO samples, Rps23rg1 defi-
ciency resulted in dramatically increased tau phosphor-
ylation at major Cdk5 phosphorylation sites, S404 and
S202/T205 (probed using the AT8 antibody) [34, 35]
(Fig. 1c, d). Although Rps23rg1 deficiency also led
to increased tau phosphorylation at two minor Cdk5
phosphorylation sites, S199 and S396, effects were less
than observed with S404 and S202/T205 phospho-sites
(Fig. 1c, d). These results collectively indicate that
RPS23RG1 is important for tau phosphorylation regula-
tion and axon outgrowth.
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Cdk5-p35 is important for RPS23RG1-mediated tau
phosphorylation
To elucidate potential mechanisms underlying RPS23RG1-
mediated tau phosphorylation, we assayed potential changes
in total levels in tau kinases such as GSK-3β and Cdk5. We
observed no change in protein levels of these components in
Rps23rg1 KO neurons (Fig. 2a) or hippocampal samples
(Fig. 2b) compared to WT. However, we observed a slight
reduction in phosphorylated GSK-3β (S9) levels in
Rps23rg1 KO samples, suggesting that GSK-3β activity
may be enhanced with Rps23rg1 deletion (Fig. 2a, b); this is
consistent with previous observations that overexpression of
RPS23RG1 reduced GSK-3β activity [26, 27]. Interestingly,
we found that protein levels of p35 and its cleavage product,
p25 were markedly increased in Rps23rg1 KO samples
(Fig. 2a, b), implicating potential involvement of the Cdk5-
p35 complex in RPS23RG1-mediated tau phosphorylation.
To confirm this, we overexpressed RPS23RG1 and p35
individually or together in a HEK293 cell line stably
expressing the longest human tau isoform tau441 (HEK293/
tau) [36]. As expected, p35 overexpression promoted tau
phosphorylation at all sites studied here (S404, S202/T205,
S199, and S396), with relatively higher effects on p35
major phosphorylation sites (S404 and S202/T205) com-
pared to minor phosphorylation sites (S199 and S396)
(Fig. 2c). RPS23RG1 overexpression attenuated tau phos-
phorylation at all sites studied in HEK293/tau cells; and its
overexpression in p35-overexpressing cells also reversed
tau hyperphosphorylation and reduced p35 protein levels
(Fig. 2c). In cells overexpressing p35, treatment with
the Cdk5-specific inhibitor roscovitine dose-dependently
reversed tau phosphorylation mainly at S404 and S202/
T205 without affecting p35 levels, whereas treatment with
the GSK-3β inhibitor TDZD-8 dose-dependently reversed
tau phosphorylation mainly at S199 and S396 (Fig. 2c).
Analysis using immunofluorescence imaging also showed
that RPS23RG1 overexpression reduced phospho-S404 tau
fluorescence in HEK293/tau cells (Fig. 2d), and reversed
the elevation of phospho-S404 tau signals induced by p35
overexpression (Fig. 2e). These results suggest that in
addition to GSK-3β, the Cdk5-p35 pathway also plays an
important role in RPS23RG1-mediated tau phosphorylation.
RPS23RG1 mediates homeostatic proteasomal p35
turnover
In order to determine how RPS23RG1 regulates p35 levels,
we performed quantitative real-time PCR (RT-PCR) ana-
lysis to characterize p35 mRNA levels with RPS23RG1
modulation. No significant differences in p35 mRNA levels
were detected between Rps23rg1 KO and WT samples
Fig. 1 Rps23rg1 KO mice feature increased tau phosphorylation
and impaired axon elongation. a, b Hippocampal neurons from WT
and Rps23rg1 KO mice at postnatal day 0 (P0) were immunostained
for Tuj-1 at 2 days in vitro (DIV2) (a) and DIV4 (b). Immuno-
fluorescence images were obtained by confocal microscopy. Axon
length was quantified using ImageJ for comparison. Data represent
mean ± SEM (n= 30 neurons from 3 mice per group, with the mean of
WT set to one arbitrary units, A.U.). Scale bars= 10 μm. c, d Protein
lysates from P0 WT and Rps23rg1 KO mouse hippocampal neurons at
DIV2 and DIV4 (c), and P0 and P7 hippocampal tissues (d) were
subjected to immunoblotting for the proteins indicated. Protein levels
were quantified by densitometry, normalized to β-actin levels, and
compared to respective WT controls (set to one A.U., indicated by
dashed lines). Data represent mean ± SEM (n= 3 per group). *p <
0.05, ***p < 0.001 (two-tailed Student’s t-test).
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(Fig. S1), suggesting that RPS23RG1 does not affect p35
transcription. We then treated hippocampal neuron cultures
derived from Rps23rg1 KO and WT mice with cyclohex-
imide (CHX) to inhibit protein synthesis and quantified p35
protein degradation kinetics. We found that p35 degradation
was significantly slower in Rps23rg1 KO neurons compared
to WT controls (Fig. 3a). In contrast, in RPS23RG1-over-
expressing cells, p35 showed faster degradation compared
to control cells (Fig. 3b).
Previous studies demonstrate that p35 is primarily
degraded through the ubiquitin-proteasome pathway
[37, 38]. We also confirmed that the degradation of
endogenous p35 (Fig. S2a) and exogenous p35 upon
RPS23RG1 co-expression (Fig. S2b) could be inhibited by
the proteasomal inhibitor MG-132 but not the lysosomal
inhibitor NH4Cl. Moreover, levels of high molecular
weight, poly-ubiquitin conjugated p35 immunoprecipitates
were reduced in Rps23rg1 KO mouse hippocampal lysates
compared to WT controls (Fig. 3c). In contrast, increased
high molecular weight, poly-ubiquitin conjugated p35
bands were observed with RPS23RG1 overexpression
(Fig. 3d). These findings suggest that RPS23RG1
Fig. 2 RPS23RG1 attenuates tau phosphorylation through the
Cdk5/p35 pathway. a, b Protein lysates from postnatal day 0 (P0)
WT and Rps23rg1 KO mouse hippocampal neurons at DIV2 and
DIV4 (a), and P0 and P7 hippocampal tissues (b) were subjected to
immunoblotting for the proteins indicated. Protein levels were quan-
tified by densitometry, normalized to β-actin levels, and compared to
respective WT controls (set to one arbitrary units, A.U., indicated by
dashed lines). Data represent mean ± SEM (n= 3). c HEK293/tau cells
were transfected with pcDNA3.1-Myc control or p35-Myc vectors for
6 h, and subsequently transfected with pCMV-HA control or HA-
RPS23RG1 (RR1) vectors, or treated with increased doses of ros-
covitine (Ros, 5–25 μM) or TDZD-8 (5–25 μM) for another 18 h.
Protein lysates were subjected to immunoblotting for the proteins
indicated. Protein levels were quantified for comparison to respective
controls (with the mean of control cells set to one A.U.). Data repre-
sent mean ± SEM (n= 3). d HEK293/tau cells were transfected with
HA-RR1. After immunostaining of HA-RR1 (d1, red) and tau pS404
(d2, green), cells were imaged by confocal microscopy. Three areas in
merged images (d3) were enlarged to show pS404 intensity in cells
with (d3’’ and d3’’’, indicated by arrows) or without (d3’, indicated by
arrowheads) HA-RR1 expression. Intensity of pS404 was quantified.
Data represent mean ± SEM (n= 20 cells in each group, with the mean
of the intensity in cells with no HA-RR1 expression set to one A.U.).
e HEK293/tau cells were co-transfected with HA-RR1 and p35-Myc
for 24 h. After immunostaining for HA-RR1 (e1, red), p35-Myc (e2,
white), and tau pS404 (e3, green), cells were imaged by confocal
microscopy. Two areas in merged images (e4) were enlarged to show
pS404 intensity in cells expressing p35-Myc alone (e4’, indicated by
arrowheads) and in cells co-expressing HA-RR1 and p35-Myc (e4’’,
indicated by arrows). The intensity of pS404 was quantified for
comparison. Data represent mean ± SEM (n= 26 cells in each group,
with the mean of the intensity in cells with no HA-RR1 and p35-Myc
expression set to one A.U.). Scale bars= 10 μm. *p < 0.05, **p < 0.01,
***p < 0.001 (two-tailed Student’s t-test).
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facilitates p35 turnover through the ubiquitin-proteasome
pathway.
RPS23RG1 interacts with p35 and mediates p35
distribution to membranes
P35 is distributed to membranes through N-terminal myr-
istoylation at G2, and membrane localization has been
previously shown to be prerequisite for p35 degradation
[20, 21]. To determine whether RPS23RG1-dependent p35
turnover requires p35 localization at membranes, we com-
pared p35 levels in the membrane and cytosolic fractions.
We found that membrane-bound p35 and soluble p35 levels
were significantly decreased and increased, respectively,
in Rps23rg1 KO hippocampal neurons compared to WT
controls (Fig. 4a). In contrast, RPS23RG1 overexpression
significantly increased membrane-associated p35 levels and
reduced soluble p35 levels (Fig. 4b).
To elucidate how RPS23RG1 regulates p35 membrane
localization, we characterized potential RPS23RG1
interactions with p35. Indeed, exogenously-expressed
RPS23RG1 showed marked colocalization with exogen-
ous p35 in Hela cells (Fig. 4c), and with endogenous p35 in
hippocampal neurons (Fig. 4d). Moreover, we generated
various RPS23RG1 and p35 truncated constructs (Fig. 4e)
and assayed binding by co-immunoprecipitation. We found
that full-length p35 interacted with full-length RPS23RG1
(Fig. 4f) but not RR1△C that lacks RPS23RG1 intracel-
lular carboxyl-terminal region (Fig. 4g). Full-length
RPS23RG1 interacted with a p35 N-terminal fragment
(N10) (Fig. 4h). Moreover, we observed that endogenous
RPS23RG1 interacted with full-length p35 but not p25 in
mouse brain lysates (Fig. 4i), further indicating that the p35
N-terminus is essential for RPS23RG1 interaction. We also
found that overexpression of RR1△C had no effect on
promoting p35 poly-ubiquitination (Fig. 3d) and p35
membrane distribution (Fig. 4b). Together, these results
demonstrate that the RPS23RG1 intracellular domain
interacts with the p35 amino-terminus to facilitate p35
membrane anchoring. Interestingly, mutation of the p35
myristoylation site (G2A) did not affect its interaction with
RPS23RG1 (Fig. S3), implying that the binding of
RPS23RG1 to p35 does not require p35 myristoylation and
that membrane-binding of p35 may be facilitated indepen-
dently through its myristoylation and its interaction with
RPS23RG1.
Mouse Rps23rg2 is a functional homolog to Rps23rg1.
We found no change in Rps23rg2 expression in Rps23rg1
KO mice compared to controls, suggesting that there are no
compensatory changes in Rps23rg2 levels with Rps23rg1
deletion (Fig. S4a). We also found that both mouse
RPS23RG1 and RPS23RG2 interacted with p35 (Fig. S4b),
and overexpression of both proteins enhanced p35 mem-
brane distribution and reduced p35 levels (Fig. S4c).
Fig. 3 RPS23RG1 promotes proteasomal p35 turnover. a, b Cul-
tured primary neurons from WT and Rps23rg1 KO mice (a), and
HEK293T cells co-transfected with p35-Myc and pCMV-HA (Con) or
HA-RPS23RG1 (RR1) (b) were treated with 30 μM cycloheximide
(CHX) for the time indicated. P35 levels were determined by immu-
noblotting, quantified by densitometry, and normalized to β-actin
levels (values at the 0 h time point were set to one arbitrary units,
A.U.). Data represent mean ± SEM (n= 3). *p < 0.05, **p < 0.01
(two-tailed Student’s t-test). c, d Protein lysates from WT and
Rps23rg1 KO mouse hippocampal tissues (c), and HEK293T cells co-
transfected with p35-Myc and control (Con), HA-RR1, or HA-
RR1△C plasmid for 24 h (d) were subjected to immunoprecipitation
(IP) with an antibody against p35. Precipitates were determined by
immunoblotting (IB) with an antibody against ubiquitin (Ubiq). Ten
percent of IP lysates were used as input and subjected to immuno-
blotting for the proteins indicated.
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However, the effects of RPS23RG2 on modulating p35
levels and membrane distribution were weaker compared to
mouse and human RPS23RG1 (Fig. S4c). One possible
explanation may be that sequences in the longer carboxyl-
terminal tail in RPS23RG2 reduces its binding to p35.
P35 downregulation and Cdk5 activity inhibition
rescue tau hyperphosphorylation and impaired
axon outgrowth in Rps23rg1 KO neurons
To verify that elevated p35 levels can induce tau
hyperphosphorylation and axon outgrowth impairment in
Rps23rg1 KO mice, we designed three p35-targeting siR-
NAs and assayed these siRNAs for p35 knockdown effi-
ciency (Fig. 5a). Using two p35-targeting siRNA oligos to
deplete p35 in Rps23rg1 KO neurons, we found that tau
phosphorylation at major Cdk5 phospho-sites (S404 and
S202/T205) was significantly reduced, and tau phosphor-
ylation at minor Cdk5 phospho-sites (S199 and S396) was
slightly reduced (Fig. 5b). Furthermore, treatment with
roscovitine dose-dependently attenuated tau phosphoryla-
tion at S404 and S202/T205, and treatment with TDZD-8
dose-dependently attenuated tau phosphorylation at S199
and S396 (Fig. 5b). More importantly, we found that p35
Fig. 4 RPS23RG1 interacts with p35 to regulate p35 membrane
anchoring. a, b Protein lysates from cultured hippocampal WT and
Rps23rg1 KO mouse neurons at DIV4 (a), and of HEK293T cells
co-transfected with p35-Myc and control (Con), HA-RR1, or HA-
RR1△C plasmid (b) were subjected to cytoplasm (Cyt) and mem-
brane (Mem) fractionation. P35 levels were determined by immuno-
blotting and quantified by densitometry for comparison. Data represent
mean ± SEM (n= 4 for neurons and 3 for HEK293T, with the mean
of controls set to one arbitrary units, A.U.). ns p > 0.05, **p < 0.01,
***p < 0.001 (two-tailed Student’s t-test). c Hela cells were co-
transfected with HA-RR1 and p35-Myc for 24 h. After immunostain-
ing with antibodies against HA (for RR1, green) and Myc (for p35,
red), cells were counterstained with DAPI and observed by confocal
microscopy. Scale bars =10 μm. d WT mouse primary neurons were
transfected with HA-RR1 at DIV3, and immunostained with
antibodies against HA (for RR1, green) and p35 (red) and counter-
stained with DAPI at DIV4. Images were acquired by confocal
microscopy. Scale bars= 10 μm. e Schematic depictions of human
RR1 and p35 and their truncated constructs. Full-length RR1 com-
prises a single transmembrane (TM) domain. RR1△C lacks the car-
boxyl (C)-terminal intracellular region. P35 is cleaved into an amino
(N)-terminal (1–98) N10 fragment and a C-terminal (99–307) p25
fragment by calpain. f–h HEK293T cells were co-transfected with
p35-Myc and HA-RR1 (f), p35-Myc and HA-RR1△C (g), or p35-
N10-Myc and HA-RR1 (h). Cell lysates were subjected to immuno-
precipitation (IP) with antibodies against HA and Myc and control
immunoglobulin G (IgG), and immunoblotted (IB) for the components
indicated. i WT mouse brain lysates were subjected to IP with an
antibody against mouse RR1 and immunoblotted with an antibody
against both p35 and p25, or the antibody against RR1.
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downregulation significantly ameliorated impaired axon
elongation in Rps23rg1 KO neurons (Fig. 5c). Treatment
with roscovitine also enhanced axon outgrowth in Rps23rg1
KO neurons (Fig. 5d). In order to confirm that results using
siRNAs were not due to off-target effects, we constructed a
p35 expression construct comprising silent mutations (SM)
refractory to targeting by siRNA #1 oligos. Overexpression
of wild type and SM p35 plasmids comparably induced tau
hyperphosphorylation in HEK293/tau cells. However,
additional transfection of p35 siRNA #1 only reduced p35
levels and tau phosphorylation in cells expressing wild type
p35 but not p35 SM mutant (Fig. S5). These results confirm
that hyperphosphorylation and axon outgrowth impairment
in Rps23rg1 KO mice is triggered by elevated p35 levels
and enhanced Cdk5 activation.
RPS23RG1 overexpression attenuates tau
hyperphosphorylation and axon outgrowth defects
in P301L tau Tg neurons
Cumulative evidence indicates that Cdk5 is aberrantly
activated in brains from the murine P301L tau Tg tauopathy
model, where Cdk5 inhibition attenuated tau pathology in
these mice [39, 40]. Interestingly, we found that RPS23RG1
Fig. 5 Downregulation of p35 and inhibition of Cdk5 activity
attenuate tau phosphorylation and rescue impaired axon out-
growth in Rps23rg1 KO neurons. a Cultured hippocampal neurons
from P0 Rps23rg1 KO mice were transfected with scrambled control
(SC) or various p35 siRNAs (#1–3) at DIV0. Three days later, cell
lysates were immunoblotted for p35. P35 protein levels were quanti-
fied by densitometry, normalized to β-actin levels, and compared to SC
(set to one arbitrary units, A.U.). Data represent mean ± SEM (n= 4).
b Hippocampal neurons from P0 Rps23rg1 KO mice were transfected
with p35 siRNAs (#1 and #2) or SC siRNA for 72 h, or treated with
increased doses of roscovitine (Ros, 5–25 μM) and TDZD-8
(5–25 μM) for 24 h. Cells lysates were immunoblotted for the pro-
teins indicated. Protein levels were quantified and compared to
SC siRNA (set to one A.U.). Data represent mean ± SEM (n= 3).
c, d Hippocampal neurons from P0 Rps23rg1 KO mice were trans-
fected with SC and p35 siRNAs (c), or treated with Ros (5 and 25 μM)
(d) at DIV0. At DIV2 or DIV4, cells were immunostained for Tuj-1.
Immunofluorescence images were acquired by confocal microscopy.
Axon length was quantified using ImageJ for comparison. Data
represent mean ± SEM (n= 30 neurons from 3 mice per group). Scale
bars= 10 μm. ns p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001 (two-
tailed Student’s t-test).
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protein levels were reduced, whereas p35 and p25 protein
levels were elevated in P301L tau Tg mouse hippocampal
samples compared to littermate controls (Figs. 6a and S6a).
In addition, P301L tau Tg mouse hippocampal neurons
exhibited dramatically increased tau phosphorylation and
impaired axon outgrowth compared to WT controls
(Fig. 6b). Moreover, we found that overexpression of
P301L tau but not WT tau dramatically reduced RPS23RG1
levels in HEK293T cells (Fig. S6b).
To elucidate a potential role for RPS23RG1 in tau
phosphoregulation in tauopathy, we overexpressed
RPS23RG1 in HEK293/tau cells (Fig. S7) and P301L tau
Tg mouse hippocampal neurons (Figs. 6c and S8). As
expected, overexpression of RPS23RG1 significantly
Fig. 6 RPS23RG1 overexpression mitigates tau hyperpho-
sphorylation and promotes axon outgrowth in tau P301L Tg
mouse neurons. a Hippocampal neurons from P0 WT and P301L tau
Tg mice at DIV4 were subjected to immunoblotting for the proteins
indicated. Protein levels were quantified by densitometry, normalized
to β-actin levels, and compared to WT (set to one arbitrary units,
A.U.). Data represent mean ± SEM (n= 3). b Hippocampal neurons
from P0 P301L tau Tg mice were immunostained for Tuj-1 (green) and
pS404 (red) at DIV4. Immunofluorescence images were obtained by
confocal microscopy. Axon length and pS404 intensity were quanti-
fied using ImageJ. Data represent mean ± SEM (n= 26 neurons from
3 mice per group, with the mean of WT set to one A.U.). Scale bars=
10 μm. c Hippocampal neurons from P0 P301L tau Tg mice were
transfected with pCMV-HA control (Con) or HA-RPS23RG1 (RR1) at
DIV3 for 24 h. Cell lysates were subjected to immunoblotting for the
proteins indicated. Protein levels were quantified and compared to
controls (set to one A.U., indicated by the dashed line). Data represent
mean ± SEM (n= 3). d Hippocampal neurons from P0 P301L tau Tg
mice were transfected with Con or HA-RR1 vectors. Total lysates
were subjected to immunoprecipitation (IP) with an antibody against
p35 and immunoblotting (IB) with an antibody against ubiquitin
(Ubiq). Ten percent of IP lysates were used as input and
immunoblotted for the proteins indicated. Alternatively, treated cells
were subjected to membrane (Mem) fractionation and the proteins
indicated in membrane fractions were detected by immunoblotting.
e Hippocampal neurons from P0 P301L tau Tg mice were transfected
with HA-RR1 at DIV3 for 24 h. Cells were co-immunostained for HA-
RR1 (e2 and e2’, green) and pT205 (e3, red) or pS404 (e3’, red). Cells
expressing HA-RR1 were identified by single-channel image merging
(e1 and e1’). Representative cells with (e3-1 and e3’-1) and without
(e3-2 and e3’-2) HA-RR1 expression were enlarged for pT205 (e3-1
and e3-2) and pS404 (e3’-1 and e3’-2) intensity quantitation using
ImageJ. Data represent mean ± SEM (n= 15 cells for each group, with
mean immunofluorescence intensity in cells without HA-RR1
expression set to one A.U.). Scale bars= 10 μm. f Hippocampal
neurons from P0 P301L tau Tg mice were transfected with Con or HA-
RR1 at DIV3 for 24 h. Cells were co-immunostained for HA-RR1
(red) and Tuj-1 (green). Immunofluorescence images were acquired by
confocal microscopy. Axon length was quantified using ImageJ.
Data represent mean ± SEM (n= 25 neurons from 3 mice in
each group, with the mean of those of control cells set to one A.U.).
Scale bars= 10 μm. *p < 0.05, **p < 0.01, ***p < 0.001 (two-tailed
Student’s t-test).
RPS23RG1 modulates tau phosphorylation and axon outgrowth through regulating p35 proteasomal degradation
reduced tau phosphorylation at both major and minor Cdk5
phosphorylation sites, without affecting total tau levels.
RPS23RG1 overexpression also increased high molecular
weight, poly-ubiquitin conjugated p35 bands in P301L tau
Tg mouse neurons (Fig. 6d). Consistent with these results,
immunostaining assays showed that RPS23RG1 over-
expression reduced tau phosphorylation at S404 and T205
phospho-sites in primary neurons from P301L tau Tg mice
(Fig. 6e). Importantly, RPS23RG1 overexpression also
increased axon length in P301L tau Tg neurons (Fig. 6f).
Together, these findings demonstrate that RPS23RG1
overexpression can arrest tau hyperphosphorylation and
promote axon outgrowth in P301L tau Tg mice.
Discussion
RPS23RG1 is a recently characterized membrane protein
with physiological and pathological functions that have yet
to be fully elucidated. Previous studies suggest that the
RPS23RG1 transmembrane domain can interact with ade-
nyl cyclases to activate the cAMP/PKA/GSK-3β pathway,
thereby inhibiting Aβ generation and tau phosphorylation.
The RPS23RG1 intracellular domain can also interact
with PSD-93 and PSD-95 to maintain PSD architecture,
implicating a role for RPS23RG1 in AD [26–28]. In this
study, we identified an additional physiological function for
RPS23RG1 in mediating homeostatic p35 proteasomal
degradation, thereby restricting Cdk5-p35-mediated tau
phosphorylation and facilitating axon outgrowth (Fig. 7).
More importantly, we observed that RPS23RG1 levels were
markedly decreased in P301L tau Tg mice; and RPS23RG1
overexpression ameliorated tau hyperphosphorylation and
axon outgrowth deficits.
Hyperphosphorylated tau is neurotoxic, and aggregates
to form intracellular neurofibrillary tangles that pathologi-
cally manifest in AD and related tauopathy disorders
[41, 42]. Therefore, inhibiting tau hyperphosphorylation is a
therapeutically relevant strategy in limiting neurodegen-
erative effects in these disorders. Tau hyperphosphorylation
is primarily induced by aberrant activation of Cdk5 and
GSK-3β [35, 43, 44]. Herein, we provide both in vivo and
in vitro evidence that RPS23RG1 can also regulate tau
phosphorylation by modulating Cdk5-p35 activity. Cdk5
and its relatively unstable regulatory p35 subunit have been
shown to play an important role in cytoskeletal organization
and neurite outgrowth [45, 46]. P35-deficient mice feature
abnormal neuronal layer development and as well as defects
in cognition [47, 48]. Enhanced conversion of p35 to p25
with neurotoxic insult results in aberrant Cdk5 activation,
leading to tau pathological hyperphosphorylation and cell
death in AD and other tauopathic disorders [49–51]. These
findings indicate that the homeostatic regulation of p35
protein levels is vital in tau phospho-regulation and neurite
extension. To this point, molecular mechanisms underlying
p35 regulation remain largely unknown. Our current study
reveals a new route for p35 homeostasis maintenance by
RPS23RG1.
As an additional kinase characterized in pathological tau
phosphorylation, GSK-3β has been previously shown to
act downstream of RPS23RG1, where RPS23RG1 over-
expression reduces tau phosphorylation by attenuating GSK-
3β activity [26, 27]. Indeed, we observed a slight increase in
GSK-3β activity through reduced phosphorylation at GSK-3β
S9 in Rps23rg1 KO mice. Although all tau sites characterized
in this study are potential GSK-3β phospho-sites, Rps23rg1
deletion potentiated phosphorylation to a greater extent at
major Cdk5 phospho-sites (S404 and S202/T205; >3 fold
increase) compared to minor Cdk5 phospho-sites (S199 and
S396; <2 fold increase) (Fig. 1). These results suggest that
loss of RPS23RG1 may substantially promote Cdk5 activity
and that this may have stronger effects than that seen with
enhancing GSK-3β activity. Furthermore, overexpression of
full-length RPS23RG1 dramatically reduced tau phosphor-
ylation at phospho-sites described here. While overexpression
of an RPS23RG1 C-terminal deletion construct (RR1ΔC)
refractory to p35 binding had little effect on reducing tau
phosphorylation at S404 and S202/T205 phospho-sites, this
construct still significantly reduced tau phosphorylation at
S199 and S396 which are also GSK-3β phospho-sites
Fig. 7 Schematic diagram of RPS23RG1 (RR1) regulating tau
phosphorylation by modulating p35/Cdk5 and GSK-3β. Under
physiological conditions, the RR1 C-terminus interacts with the p35
N-terminus to facilitate p35 membrane-binding and degradation, thus
suppressing Cdk5 activity. In addition, the trans-membrane domain
of RR1 interacts with adenylate cyclases (AC) to promote cAMP
production, leading to upregulated protein kinase A (PKA) activity
to reduce GSK-3β activity. Thus, RR1 controls normal tau phos-
phorylation and facilitates physiological axon outgrowth. Rps23rg1
deletion in mice or reduced RR1 in tauopathies triggers membrane-
bound p35 release into the cytosol, impairs p35 degradation, and
downregulates AC/cAMP/PKA signaling. Consequent pathogenic
activation of Cdk5 and GSK-3β results in tau hyperphosphorylation
and impaired axon outgrowth.
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(Fig. S8). These findings demonstrate that RPS23RG1 can
regulate tau phosphorylation by modulating both GSK-3β and
Cdk5-p35 activity. However, loss of RPS23RG1 may have
greater effects on Cdk5-p35 over GSK-3β. Given that cross-
talk between GSK-3β and Cdk5-p35 pathways have been
revealed previously [52, 53], regulatory effects of RSP23RG1
on these two kinases may be more complicated than what we
describe here, and their interplay under various pathophy-
siological conditions warrants further scrutiny.
We previously found that RPS23RG1 expression was
decreased in the postmortem AD brain and that Aβ treat-
ment markedly reduced RPS23RG1 levels [28]. Herein, we
found that RPS23RG1 levels were significantly decreased
in P301L tau Tg mice compared to WT mice and in cells
overexpressing P301L but not WT tau. Moreover, we
noticed that RPS23RG1 levels were further decreased in
P301L tau Tg mice during aging (Fig. S6c). Therefore,
RPS23RG1 may be reduced in response to Aβ and patho-
logic tau proteotoxicity. As RPS23RG1 signaling mod-
ulates Aβ generation, tau phosphorylation, and synaptic
function, pathological changes in Aβ, tau, and RPS23RG1
may form a vicious cycle which drives pathogenesis in AD
and other tauopathies.
In summary, we demonstrate that RPS23RG1-p35 inter-
actions promote proteasomal p35 turnover which limits phy-
siological tau phosphorylation and enhances axon outgrowth
in the brain. Since RPS23RG1 levels are decreased in P301L
tau Tg mouse brain and upon P301L tau expression, and
RPS23RG1 overexpression can attenuate tau hyperpho-
sphorylation and axon outgrowth deficits in P301L tau Tg
mouse neurons, RPS23RG1 and its downstream pathways
may be potential therapeutic targets for tauopathy.
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